Manuel Bardies, Institut de Recherche en Cancerologie de Montpellier, Montpellier, France

Manuel Bardiès obtained his Doctorate on radiopharmaceutical dosimetry from Toulouse University, France in 1991. He has been developing his research in radiopharmaceutical dosimetry within INSERM (National Institute of Health and Medical Research) since 1992 in Nantes, then in Toulouse (2011), and in Montpellier since 2021.
Manuel Bardiès was one of the founders of the EANM Dosimetry Committee (member from 2001 to 2013, chair 2009-2011). He chaired the EFOMP Science Committee between 2014 and 2016, and is currently chairing the newly established EFOMP Special Interest Group for radionuclide internal dosimetry.
He has been involved in education in various European structures (ESMIT, ESMPE). As coordinator of the Education Council of the French Society of Medical Physics for 10 years, he participated to the Board of the medical physics resident programme in France, and was appointed Professor by the French National Institute for Nuclear Science and Technology (INSTN) in June 2018 (renewed in June 2024).
The group led by Manuel Bardiès is primarily involved in radiopharmaceutical dosimetry, at various scales (cell, tissue, organ). This requires the ability to assess radiopharmaceutical pharmacokinetics in vivo, through quantitative SPECT or PET small-animal imaging or in the clinics. An important part of the research activity involves Monte Carlo modelling of radiation transport. The objective is to improve molecular radiotherapy by promoting patient-specific treatments (personalized medicine).

Elizabeth Krupinski, Emory University, Atlanta, USA

Dr. Krupinski is Professor and Vice-Chair of Research at Emory University in the Departments of Radiology, Psychology and Bioinformatics. She received her BA from Cornell, MA from Montclair State and PhD from Temple, all in Experimental Psychology. Her interests are in medical image perception, observer performance, decision making, human factors, and the interface between humans and computers and how that impacts clinical decision-making efficacy and efficiency. She is Past President of the American Telemedicine Association, Past Chair of the Society for Imaging Informatics in Medicine, Past Chair of the SPIE Medical Imaging Symposium, President of the Society for Education and the Advancement of Connected Health, and President of the Medical Image Perception Society. She is Editor of Telemedicine Reports and the Journal of Imaging Informatics in Medicine.

Cynthia H. McCollough, Mayo Clinic, Rochester, USA

A recognized leader in the development and evaluation of new CT technology and dose reduction methods, Cynthia H. McCollough, PhD, is the Brooks-Hollern Professor at the Mayo Clinic in Rochester, Minnesota, where she holds the rank of professor in both medical physics and biomedical engineering. Dr. McCollough is a fellow of the American College of Radiology, the American Association of Physicists in Medicine, and the American Institute for Medical and Biological Engineering. She has over 500 peer-reviewed papers and multiple NIH grants related to CT imaging. She has served as the president of the American Association of Physicists in Medicine and is a vice-president of the International Society of Computed Tomography. She received her master's and doctorate degrees in medical physics at the University of Wisconsin, Madison after graduating in physics from Hope College in Holland, Michigan. The first whole-body, high-flux photon counting detector CT system was installed in her lab in 2014 and she has played a key role in the development of photon counting CT since that time.

Michael Schöll, University of Gothenburg, Gothenburg, Sweden

Michael Schöll is Professor of Molecular Medicine at the Wallenberg Centre for Molecular and Translational Medicine at the University of Gothenburg, Principal Research Fellow at the Queen Square Institute of Neurology at University College London, BrainPool Fellow of the National Research Foundation of Korea and elected member of the Young Academy of Sweden.  His work focuses on developing, establishing and validating clinically relevant biomarkers for the early and robust identification of neurodegenerative diseases such as Alzheimer’s disease. He was awarded the Queen Silvia Prize to a Young Scientist and the Birger Karlsson Science Award and has been ranked among the 0.1% most-cited scientists by Web of Science continuously since 2020.

Mika Kortesniemi, HUS Medical Imaging Center, University of Helsinki, Helsinki, Finland

New ICRP publication on optimization in radiology